Michael Chuong/mapquest.com
Jun 22, 2025, 10:33
Michael Chuong: Excited That the Phase 3 NRG ONCOLOGY GI011 Trial in Locally Advanced Pancreatic Cancer Has Been Activated
Michael Chuong, Vice Chair and Medical Director of the Department of Radiation Oncology at Miami Cancer Institute, shared a post on LinkedIn:
“I’m really excited that the phase 3 NRG ONCOLOGY GI011 trial (NCT06958328) has been activated, which randomizes patients with locally advanced pancreatic cancer after induction chemotherapy to ablative radiation therapy vs. standard of care chemotherapy/radiation therapy or observation.
The primary endpoint is 3-year OS, based off promising data including some from Baptist Health Miami Cancer Institute and Florida International University – Herbert Wertheim College of Medicine suggesting that ablative radiation therapy can meaningfully extend long-term OS.
This study has the potential to be paradigm changing as prior randomized trials using standard lower radiation doses did not improve OS for this disease over chemotherapy alone, so please support it at your institution!
Congrats to Nina Sanford and the entire study team – now let’s get to work!”
More posts featuring Michael Chuong on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 10, 2025, 06:53
Jul 9, 2025, 23:47
Jul 9, 2025, 23:31
Jul 9, 2025, 23:14
Jul 9, 2025, 23:06
Jul 9, 2025, 22:41